LGC and AKOS combine to offer expanded drug development services


LGC has formed a strategic alliance with AKOS, the UK-based specialist drug development and regulatory affairs consultancy company, that will enable both parties to expand the range of services they offer to drug discovery companies. AKOS specialises in leading clients from drug discovery through the development process, and has a strong track record of enabling organisations to achieve their strategic aims, including onward sale or licensing, through to marketing authorisation. LGC offers a wide range of analytical services and instrumentation that are applied across the drug development cycle from early phase discovery through to clinical trial. Through this alliance clients will benefit from the best in advice and services that will enhance the development and valuation of new products.

Other news from the department business & finance

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics